Charter Oak Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Charter Oak Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-925	Closed	-$13K	–	161
2022 Q2	$13K	Hold	925	–	–	﹤0.01%	543
2022 Q1	$22K	Hold	925	–	–	﹤0.01%	488
2021 Q4	$22K	Hold	925	–	–	﹤0.01%	482
2021 Q3	$15K	Hold	925	–	–	﹤0.01%	502
2021 Q2	$23K	Buy	925 +200	+28%	+$4.51K	﹤0.01%	427
2021 Q1	$33K	Hold	725	–	–	﹤0.01%	368
2020 Q4	$33K	Buy	+725	New	+$36K	0.01%	351

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Charter Oak Capital Management's ACAD Position: Q3 2022 in Review

Charter Oak Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2022, closing a stake of 925 shares — an estimated $13K sold.

Charter Oak Capital Management first reported a position in ACAD in Q4 2020 and held it in 7 quarters. The position peaked at $33K in Q1 2021. 223 funds tracked by Wall St. Rank hold ACAD as of Q3 2022.

Charter Oak Capital Management reported no remaining Acadia Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Charter Oak Capital Management sold 925 Acadia Pharmaceuticals shares in Q3 2022, an estimated $13K.
Charter Oak Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Charter Oak Capital Management's Acadia Pharmaceuticals position peaked at $33K in Q1 2021.
223 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2022.

Based on Charter Oak Capital Management's 13F filing for Q3 2022, filed 6 Dec 2022.